



AIDS MALIGNANCY CONSORTIUM (AMC) AMC Operations & Data Management Center (ODMC)
The Emmes Company, LLC
401 N. Washington Street, Suite 700
Rockville, MD 20850
Phone: 301-251-1161; Fax: 240-238-2842

PRESS RELEASE

AMC FELLOWSHIP PROGRAM

Rockville, Maryland (DATE): The AIDS Malignancy Consortium (AMC) is pleased to announce the recipients of the 2019 **AMC Fellowship Program**. The fellowship program was established to encourage and foster the development of new and junior clinical investigators at our domestic and international sites to pursue careers in clinical research trials in HIV-associated malignancies within the context of the AMC. These fellowships are designed to allow the fellow to have dedicated time to participate in the scientific and clinical trials aspects of the AMC. The 2019 AMC Fellowship Recipients are:

Domestic

- Stephen Kimani, MD, MSc (University of North Carolina in Chapel Hill, USA)
- Rafi Kabbariti, MD (Albert Einstein Comprehensive Cancer Center, USA)

International

- Jose A. E. Barletta, MD (Hospital Fernández, Argentina)
- Carlos Frederico L. Benevides, PhD (Complexo Hospitalar Universitário Professor Edgard Santos, Brazil)
- Clement Dove Okello, MBBS, MD (Uganda Cancer Institute, Uganda)
- Tamiwe Tomoka, MBBS, FCPATH (UNC Project-Malawi, Malawi)
- Bongani Kaimila, MBBS, MSc, PhD (UNC Project-Malawi, Malawi)

Lab/Translational

- Rena Xian, MD (Johns Hopkins University, USA)

In addition, we congratulate the following second year AMC International and Domestic Fellows who have demonstrated adequate progress and participation in AMC activities during their first-year fellowship:

- Alison G. Chang, MD (University of California, Los Angeles, USA)
- Grant Ellsworth, MD (Weill Medical College of Cornell University, USA)
- Kate Westmoreland, MD (University of North Carolina in Chapel Hill, USA)
- Marta Epeldegui, PhD (University of California, Los Angeles, USA)
- Ryan McNamara, PhD (University of North Carolina in Chapel Hill, USA)
- Lucas Faustine Kiyeki, MD (Bugando Medical Centre, Tanzania)
- Edith Matsikidze, MBChB (University of Zimbabwe, Zimbabwe)

About the AMC

The ***AIDS Malignancy Consortium (AMC)*** develops and conducts innovative trials for HIV-infected patients with AIDS-related cancers. The AMC is a National Cancer Institute-supported clinical trials group founded in 1995 and is composed of 38 clinical trial sites worldwide, five Working Groups, an Administrative Office, a Statistical Office, and an Operations and Data Management Office. Collectively, these components develop and oversee the scientific agenda, manage the groups' portfolio of clinical trials and other scientific-based studies, and help to develop new protocols. The AMC mission is to investigate new treatment and prevention interventions for malignancies in people living with HIV and to study the pathobiology of these tumors in the context of clinical trials. The Working Groups that deal with the cancers that affect HIV-positive patients are Kaposi Sarcoma, Lymphoma, Human Papillomavirus-related Cancers (for example, anal and cervical cancers), and Non-AIDS Defining Cancers (such as, lung cancer, head and neck cancer, liver cancer). The Laboratory Working Group oversees the Central Laboratories of the AMC and develops laboratory studies to answer important scientific questions related to cancer in HIV-positive patients.

For more information about HIV-malignancies, please visit our website:

<http://www.AIDSCancer.org>